Menten AI Company

Menten AI designs new protein drugs and enzymes using quantum computers and machine learning. Proteins are large molecules that can twist into many shapes. Discovering the right shape for a protein to be a drug or a biocatalyst among almost endless possibilities is a major challenge. Menten AI solves this problem by using machine learning and quantum computing to find better starting points for discovery and further development. Quantum computing makes it possible to represent multiple states of the protein simultaneously and efficiently find the best designs. The team created the world’s first peptide designed on a quantum computer and is now working on peptide therapeutics for oncology and neurodegeneration, as well as on enzymes for industrial applications.
Technology: Artificial Intelligence, Biotechnology, Chemical, Health Care, Life Science, Machine Learning, Pharmaceutical, Quantum Computing, Therapeutics
Industry: Early Drug Development
Headquarters: Palo Alto, California, United States
Founded Date: 2018-08-24
Employees Number: 1-10
Funding Status: Seed
Investors Number: 6
Total Funding: 4005000
Last Funding Date: 2020-06-30
Last Funding Type: Seed

Visit Website
info@menten.ai
https://twitter.com/menten_ai
Register and Claim Ownership